Search results
Results from the WOW.Com Content Network
Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment ...
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991. MannKind Corporation was named after its founder, Alfred E. Mann.
MannKind (NASDAQ: MNKD) Q2 2024 Earnings Call Aug 07, 2024, 9:00 a.m. ET. ... hopefully awesome news on international expansion as we go forward Afrezza and continue to drive growth and help more ...
For premium support please call: 800-290-4726 more ways to reach us
MannKind (NAS: MNKD) announced breathtaking news this week -- literally. The biotech completed patient recruitment for two phase 3 clinical trials for its insulin inhalant Afrezza. The ...
For premium support please call: 800-290-4726 more ways to reach us
Biopharmaceutical company MannKind (NAS: MNKD) is seeking FDA approval for its inhalable insulin drug, Afrezza. A decision in 2013 is expected, and the company hopes to get this drug to market as ...